In this review, we outline the association between NASH and atherosclerosis, the underlying molecular mechanisms, and the effects of incretin-based drugs, especially GLP-1 RAs, for the therapeutic management of these conditions. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatohepatitis.